Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab + XP/FP	402
Overall Study	STARTED	Placebo + XP/FP	402
Overall Study	STARTED	Pembrolizumab + FLOT Cohort	100
Overall Study	STARTED	Placebo + FLOT Cohort	103
Overall Study	Treated	Pembrolizumab + XP/FP	399
Overall Study	Treated	Placebo + XP/FP	400
Overall Study	Treated	Pembrolizumab + FLOT Cohort	99
Overall Study	Treated	Placebo + FLOT Cohort	103
Overall Study	COMPLETED	Pembrolizumab + XP/FP	0
Overall Study	COMPLETED	Placebo + XP/FP	0
Overall Study	COMPLETED	Pembrolizumab + FLOT Cohort	0
Overall Study	COMPLETED	Placebo + FLOT Cohort	0
Overall Study	NOT COMPLETED	Pembrolizumab + XP/FP	402
Overall Study	NOT COMPLETED	Placebo + XP/FP	402
Overall Study	NOT COMPLETED	Pembrolizumab + FLOT Cohort	100
Overall Study	NOT COMPLETED	Placebo + FLOT Cohort	103

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03221426/flow